These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 1893005)

  • 21. Purification of hepatic polymorphic arylamine N-acetyltransferase from homozygous rapid acetylator inbred hamster: identity with polymorphic N-hydroxyarylamine-O-acetyltransferase.
    Trinidad A; Hein DW; Rustan TD; Ferguson RJ; Miller LS; Bucher KD; Kirlin WG; Ogolla F; Andrews AF
    Cancer Res; 1990 Dec; 50(24):7942-9. PubMed ID: 2253236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
    Grant DM; Blum M; Beer M; Meyer UA
    Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phenotypic changes in acetylation in tumor patients].
    Bulovskaia LN; Blinov NN; Simonov NN; Krupkin RG; Kolosov AI
    Vopr Onkol; 1978; 24(10):76-9. PubMed ID: 716322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Acetylation phenotype in patients with lung cancer].
    Cofta S; Lowicki Z; Młynarczyk W
    Pneumonol Alergol Pol; 1995; 63(7-8):407-9. PubMed ID: 8520558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-acetylation of drugs. Pharmacogenetic studies in rabbits selected for their acetylator characteristics.
    Weber WW; Miceli JN; Hearse DJ; Drummond GS
    Drug Metab Dispos; 1976; 4(1):94-101. PubMed ID: 3408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Occurrence of the fast acetylation phenotype in persons with the radicular syndrome. Preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Tota B; Krzysztoń Z
    Neurol Neurochir Pol; 1987; 21(6):511-5. PubMed ID: 3449771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
    Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
    Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic acetylator polymorphism in breast cancer patients.
    Ladero JM; Fernández MJ; Palmeiro R; Muñoz JJ; Jara C; Lázaro C; Pérez-Manga G
    Oncology; 1987; 44(6):341-4. PubMed ID: 3684174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphic oxidation of debrisoquine in lung cancer patients.
    Benítez J; Ladero JM; Jara C; Carrillo JA; Cobaleda J; Llerena A; Vargas E; Muñoz JJ
    Eur J Cancer; 1991; 27(2):158-61. PubMed ID: 1827280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acetylator polymorphism in rheumatoid arthritis.
    Ladero JM; Andres MP; Bañares A; Fernández B; Hernández C; Benítez J
    Eur J Clin Pharmacol; 1993; 45(3):279-81. PubMed ID: 8276055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Histochemical study of protein, its reactive groups and nucleic acids in the lungs in bronchogenic cancer].
    Piten'ko NN
    Vrach Delo; 1978 Apr; (4):48-52. PubMed ID: 664598
    [No Abstract]   [Full Text] [Related]  

  • 32. Acetylator polymorphism in Parkinson's disease.
    Ladero JM; Jimenez FJ; Benitez J; Fernandez-Gundin MJ; Martinez C; Llerena A; Cobaleda J; Muñoz JJ
    Eur J Clin Pharmacol; 1989; 37(4):391-3. PubMed ID: 2598972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetylator polymorphism in multiple sclerosis.
    Ladero JM; Arroyo R; De Andrés C; Jiménez-Jiménez FJ; Molina JA; Varela de Seijas E; Giménez-Roldán S; Benítez J
    Acta Neurol Scand; 1994 Feb; 89(2):102-4. PubMed ID: 8191871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphic N-acetylation capacity in lung cancer.
    Philip PA; Fitzgerald DL; Cartwright RA; Peake MD; Rogers HJ
    Carcinogenesis; 1988 Mar; 9(3):491-3. PubMed ID: 3345587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P
    Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acetylator phenotype in psoriasis.
    Jiménez-Nieto LC; Ladero JM; Fernández-Gundín MJ; Robledo A
    Dermatologica; 1989; 178(3):136-7. PubMed ID: 2721804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphic acetylation of procaine amide in healthy subjects.
    Karlsson E; Molin L
    Acta Med Scand; 1975 Apr; 197(4):299-302. PubMed ID: 1136858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphic acetylation of sulphamethazine in a Zimbabwe population.
    Nhachi CF
    J Med Genet; 1988 Jan; 25(1):29-31. PubMed ID: 3351888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of ethnic portraiture for predicting individual sensitivity to chemicals as exemplified by N-acetylation in cancer patients.
    Piruzjan LA; Radkevich LA; Morozova NV
    Dokl Biol Sci; 2003; 392():407-12. PubMed ID: 14650871
    [No Abstract]   [Full Text] [Related]  

  • 40. [Polymorphism of acetylation and oxidation phenotypes and the risk of neoplasms--pharmacogenetic approach to the epidemiology of neoplasms].
    Mrozikiewicz PM
    Postepy Hig Med Dosw; 1992; 46(5):531-6. PubMed ID: 1298959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.